

Africure Pharmaceuticals Ltd

(Incorporated in the Republic of Mauritius)

(Registration number: C145852 C1/GBL)

Having its registered address at

6th Floor, Tower A, 1 Cybercity, Ebene, Republic of Mauritius

(“Africure” or “the Company”)



[Africure and its subsidiaries are collectively referred to as the “Group”]

EXTENSION OF DEADLINE TO RELEASE UNAUDITED FINANCIAL RESULTS

The Board of directors (the “**Board**”) of Africure would like to apprise its shareholders and the general public that the Company will not be in a position to approve its abridged unaudited financial statements for the 3 months and 6 months ended 30 September 2023 within the 45-days deadline of its quarter end, i.e., by 14 November 2023.

The Company has accordingly obtained formal approval from the Stock Exchange of Mauritius Ltd to delay the publications of the aforementioned results until Tuesday, 21 November 2023.

By order of the Board

9 November 2023

For further information please contact:

SEM Authorised Representative & Sponsor



+230 402 0890

Company Secretary



+230 403 6000

This notice is issued pursuant to SEM Listing Rule 11.3. The Board of Africure accepts full responsibility for the accuracy of the information contained in this announcement.